{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045201","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.162032+00:00","generated_at":"2026-06-07T11:28:06.437463+00:00","sec_items":["3.03","5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SPAC Semper Paratus extends deadline to Sept 2024; $9.7M redeemed","bullets":["Shareholders approved Extension Amendment allowing up to 9-month extension to Sept 15, 2024.","Holders of 880,873 Class A shares redeemed at ~$11.02 each, aggregate ~$9.7M.","Trust account balance after redemptions and extension deposit is ~$16.5M.","Sponsor SSVK Associates deposited $67,500 for the first three-month extension.","Extension provides additional time to complete an initial business combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045201","json":"https://secwatch.observer/filing/0001493152-23-045201.json","markdown":"https://secwatch.observer/filing/0001493152-23-045201.md","text":"https://secwatch.observer/filing/0001493152-23-045201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223045201/0001493152-23-045201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223045201/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:28:06.437463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5a654316ec1ecf408475eff978450c8a682d176","claim":"Tevogen Bio Holdings Inc.: Amended charter to extend business combination deadline to September 15, 2024.","evidence_excerpt":"the Shareholders approved the Extension Amendment Proposal for the Company to adopt and file the Amended Charter","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223045201/0001493152-23-045201-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"cb67f8a276f8cecfee6dee63e2e20dbce1a2fe76","claim":"Tevogen Bio Holdings Inc. shareholders approved Extension Amendment Proposal at the 2023-11-15 meeting.","evidence_excerpt":"On the record date of November 15, 2023, the Company had 15,816,386 shares entitled to vote at the Extraordinary General Meeting. At the Extraordinary General Meeting, the Shareholders voted on one of two proposals presented, as described in the Proxy Statement, and cast their votes as described below: Proposal 1 – Extension Amendment Proposal The Shareholders approved the Extension Amendment Proposal. The following is a tabulation of the voting results: Ordinary Shares: Votes For Votes Against Abstentions Broker Non-Votes 14,359,632 5,967 0 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223045201/0001493152-23-045201-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}